PT  - JOURNAL ARTICLE
AU  - Rubina, K.
AU  - Shmakova, A.
AU  - Shabanov, A.
AU  - Andreev, Yu.
AU  - Borovkova, N.
AU  - Kulabukhov, V.
AU  - Evseev, A.
AU  - Popugaev, K.
AU  - Petrikov, S.
AU  - Semina, E.
TI  - Novel prognostic determinants of COVID-19-related mortality: a pilot study on severely-ill patients in Russia
AID  - 10.1101/2021.04.01.21254688
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.01.21254688
4099  - http://medrxiv.org/content/early/2021/04/07/2021.04.01.21254688.short
4100  - http://medrxiv.org/content/early/2021/04/07/2021.04.01.21254688.full
AB  - COVID-19 pandemic has posed a severe healthcare challenge calling for an integrated approach in determining the clues for early non-invasive diagnostics of the potentially severe cases and efficient patient stratification.Here we analyze the clinical, laboratory and CT scan characteristics associated with high risk of COVID-19-related death outcome in the cohort of severely-ill patients in Russia. The data obtained reveal that elevated dead lymphocyte counts, decreased early apoptotic lymphocytes, decreased CD14+/HLA-Dr+ monocytes, increased expression of JNK in PBMCs, elevated IL-17 and decreased PAI-1 serum levels are associated with a high risk of COVID-19-related mortality thus suggesting them to be new prognostic factors. This set of determinants could be used as early predictors of potentially severe course of COVID-19 for trials of prevention or timely treatment.Funding The reported study was funded by RFBR according to the research project № 20-24-60029.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe reported study was funded by RFBR according to the research project # 20-24-60029.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Sklifosovsky Research Institute of Emergency Medicine of the Moscow Healthcare Department (protocol #5-120, issued on 01.04.2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe findings of this study are available from the corresponding author upon reasonable request.